American Journal of Hypertension最新文献

{"title":"Hypertension Is Too Important for Healthcare Professionals Alone to Try and Solve.","authors":"Robert D Brook, Phillip D Levy, James Brian Byrd","doi":"10.1093/ajh/hpaf009","DOIUrl":"10.1093/ajh/hpaf009","url":null,"abstract":"","PeriodicalId":7578,"journal":{"name":"American Journal of Hypertension","volume":" ","pages":"203-205"},"PeriodicalIF":3.2,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11911315/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142969426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of Renal Medullary Bilirubin and Biliverdin Reductase in Angiotensin II-Dependent Hypertension.","authors":"Gertrude Arthur, Andrew R Wasson, Ross E Straughan, Heather A Drummond, David E Stec","doi":"10.1093/ajh/hpae150","DOIUrl":"10.1093/ajh/hpae150","url":null,"abstract":"<p><strong>Background: </strong>Increased circulating bilirubin attenuates angiotensin (Ang) II-induced hypertension and improves renal hemodynamics. However, the intrarenal mechanisms that mediate these effects are not known. The goal of the present study was to test the hypothesis that bilirubin generation in the renal medulla plays a protective role against Ang II-induced hypertension.</p><p><strong>Methods: </strong>Twenty-week-old male C57Bl/6J mice were implanted with intrarenal medullary interstitial (IRMI) catheters following unilateral nephrectomy. After this time, biliverdin IXα was specifically infused into the kidney (3.6 mg/day) for 3 days before implantation with an osmotic minipump delivering Ang II (1,000 ng/kg/min). BP was recorded for 3 days, 1 week after minipump infusion, in conscious mice. To further explore the antihypertensive role of renal medullary bilirubin generation, mice with specific deletion of biliverdin reductase-A (Blvra) in the thick ascending loop of Henle were generated. At 20 weeks, BlvraTALHKO and control mice (Blvrafl/fl) were infused with Ang II for 2 weeks.</p><p><strong>Results: </strong>IRMI infusion of biliverdin significantly decreased blood pressure compared with mice infused with vehicle (118 ± 4 vs. 158 ± 2 mmHg, p < 0.05). Angiotensin-II infusion resulted in significantly higher blood pressure measured in conscious mice 7 days after implantation in BlvraTALHKO as compared to Blvrafl/fl mice (152 ± 2 vs. 140 ± 3 mmHg, P < 0.05).</p><p><strong>Conclusions: </strong>Altogether, these findings show that medullary bilirubin and biliverdin reductase can improve hypertension and that mechanisms that increase bilirubin and biliverdin reductase in the renal medulla could be an effective approach to treat hypertension.</p>","PeriodicalId":7578,"journal":{"name":"American Journal of Hypertension","volume":" ","pages":"240-247"},"PeriodicalIF":3.2,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11911318/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142827045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Randomized Controlled Trial on the Efficacy and Safety of a Calcium-Channel Blocker and an Angiotensin-Converting Enzyme Inhibitor in Chinese and European Patients with Hypertension.","authors":"Wei Zhang, Chang-Yuan Liu, Grzegorz Bilo, Davide Soranna, Antonella Zambon, Konstantinos G Kyriakoulis, Anastasios Kollias, Isabella Ceravolo, Silvia Cassago, Martino F Pengo, Antonios Destounis, George S Stergiou, Ji-Guang Wang, Gianfranco Parati","doi":"10.1093/ajh/hpae152","DOIUrl":"10.1093/ajh/hpae152","url":null,"abstract":"<p><strong>Background: </strong>In a post hoc analysis of a multinational, randomized trial, we investigated whether the efficacy and safety of nifedipine-gastrointestinal therapeutic system (GITS) and ramipril differed between Chinese and European patients with hypertension.</p><p><strong>Methods: </strong>Previously treated (after 2-week washout) and untreated patients with clinic blood pressure (BP) ≥ 140/90 mmHg (systolic/diastolic), daytime ambulatory BP ≥ 135/85 mmHg and standard deviation of home systolic BP > 7 mmHg, and/or daytime BP > 12 mmHg were randomly assigned to treatment based on nifedipine-GITS 30 mg or ramipril 10 mg for 12 months. Clinic, ambulatory and home BP were measured at baseline, 10 weeks and 12 months after randomization.</p><p><strong>Results: </strong>A total of 67 Chinese and 101 European patients were analyzed and they differed in age (50.9 vs. 54.6 years, respectively), body mass index (24.5 vs. 27.0 kg/m2), clinic diastolic BP (87.9 vs. 92.5 mmHg), heart rate (75.0 vs. 70.8 beats/minute), and nighttime diastolic BP (79.3 vs. 75.9 mmHg) (all P < 0.05). However, within each ethnicity, patients were comparable for clinical characteristics between the nifedipine-GITS and ramipril groups (P > 0.05). In both the Chinese and European patients, BP was similarly reduced with nifedipine-GITS and ramipril, except that daytime systolic/diastolic BP reductions were 7.4/4.1 mmHg greater in the ramipril than nifedipine-GITS group in Chinese (P = 0.02). The safety profile differed between the Chinese and European patients (P for drug*ethnicity interaction ≤ 0.05) for all adverse events (lower incidence on nifedipine-GITS in Chinese), ankle edema (higher on nifedipine-GITS in Europeans), and dry cough (higher on ramipril in Chinese).</p><p><strong>Conclusion: </strong>In the Chinese and European patients with hypertension, nifedipine-GITS and ramipril had similar BP lowering efficacy, but different safety profile and tolerability.</p><p><strong>Clinical trials registration: </strong>Identifier at clinicaltrials.gov NCT02499822 (Registration date: 16 July 2015).</p>","PeriodicalId":7578,"journal":{"name":"American Journal of Hypertension","volume":" ","pages":"248-256"},"PeriodicalIF":3.2,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142806052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrating Proteomics and Mendelian Randomization to Identify New Therapeutic Targets.","authors":"Gaetano Santulli, Fahimeh Varzideh, Urna Kansakar, Stanislovas S Jankauskas, Scott Wilson, Pasquale Mone","doi":"10.1093/ajh/hpaf034","DOIUrl":"https://doi.org/10.1093/ajh/hpaf034","url":null,"abstract":"","PeriodicalId":7578,"journal":{"name":"American Journal of Hypertension","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143623179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oral losartan treatment improves microvascular endothelial function via nitric oxide-dependent mechanisms in women with a history of preeclampsia.","authors":"K S Schwartz, D I Jalal, A E Stanhewicz","doi":"10.1093/ajh/hpaf033","DOIUrl":"https://doi.org/10.1093/ajh/hpaf033","url":null,"abstract":"<p><strong>Background: </strong>Women with a history of preeclampsia are at increased risk of developing cardiovascular disease compared with women who had a healthy pregnancy. One potential mechanism underlying this increased risk is microvascular endothelial dysfunction, characterized by reduced nitric oxide (NO)-dependent dilation and is mediated, in part, by increased vasoconstrictor sensitivity to angiotensin II, which persists postpartum. We hypothesized that systemic angiotensin II type 1 receptor (AT1R) inhibition via once-daily oral losartan treatment would 1) improve endothelium- and NO-dependent dilation, and 2) reduce angiotensin II-mediated vasoconstriction, in the microvasculature of women with a history of preeclampsia.</p><p><strong>Methods: </strong>Eleven normotensive women, >12 weeks and ≤5 years postpartum, with a history of preeclampsia participated in a double-blind, placebo-controlled, crossover study. Following 6 weeks of placebo and losartan treatment (50 mg/day), we measured cutaneous vascular conductance responses to graded infusions of acetylcholine (ACh, 10-10-10-1M) alone or with 15mM NG nitro L-arginine methyl ester (L-NAME; NO-synthase inhibitor) to assess endothelium- and NO-dependent dilation, respectively. We also assessed microvascular vasoconstrictor responses to graded infusions of angiotensin II (10-20-10-4M) and norepinephrine (10-12-10-2M).</p><p><strong>Results: </strong>Losartan treatment increased endothelium- (P<0.001) and NO-dependent (P<0.016) vasodilation compared with placebo. Losartan treatment also reduced angiotensin II-mediated vasoconstriction (P<0.001) compared with placebo, but had no effect on norepinephrine-mediated vasoconstriction (P=0.46).</p><p><strong>Conclusions: </strong>These data suggest that systemic AT1R-inhibition with oral losartan is a viable, mechanism-specific approach to improve endothelial function and reduce vasoconstrictor sensitivity to angiotensin II in the microvasculature of healthy, normotensive women with a history of preeclampsia.</p>","PeriodicalId":7578,"journal":{"name":"American Journal of Hypertension","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143613024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation between metabolic syndrome and hyperuricemia: a systematic review and meta-analysis.","authors":"Jihuan Fan, Cuicui Bian, Jiapeng Wang, Xinyue Wang, Yanhua Cheng, Jie Lei","doi":"10.1093/ajh/hpaf031","DOIUrl":"https://doi.org/10.1093/ajh/hpaf031","url":null,"abstract":"<p><strong>Background: </strong>The main goal of this study was to conduct a meta-analysis and systematic review to examine the correlation between metabolic syndrome (MetS) and hyperuricemia.</p><p><strong>Methods: </strong>All studies available in PubMed, Cochrane Library, Embase, and Web of Science were obtained within the retrieval timeframe ending on December 9, 2023. Utilizing the Agency for Healthcare Research and Quality (AHRQ) and the Newcastle-Ottawa Scale (NOS), the included studies underwent quality appraisal, and Stata v14 software was employed for the subsequent data analysis.</p><p><strong>Results: </strong>A total of 40 studies, covering 214,091 patients, were selected based on specified inclusion and exclusion criteria. The analysis revealed a substantial association between MetS and hyperuricemia (Odds Ratio [OR] = 2.25, 95% Confidence interval [CI] 1.19-4.26, P<0.001). The metabolically abnormal overweight/obese group (MUHOWO) exhibited a heightened risk of hyperuricemia (OR = 3.54, 95%CI 2.66-4.71, P=0.002). Additionally, hyperuricemia increased the likelihood of developing MetS (OR = 2.13, 95%CI 1.63-2.79, P<0.001). Stratified by gender, hyperuricemia elevated the risk of MetS in both men (OR = 1.92, 95%CI 1.43-2.58, P<0.001) and women (OR = 2.13, 95%CI 1.62-2.8, P<0.001).</p><p><strong>Conclusions: </strong>This meta-analysis and systematic review robustly affirm a significant bidirectional association between MetS and hyperuricemia. The increased risk observed, especially in MUHOWO and across gender lines, underscores the clinical relevance. Addressing metabolic syndrome emerges as crucial in preventing and managing hyperuricemia, and vice versa. These findings offer valuable insights, urging further research into underlying mechanisms for more targeted interventions and personalized treatments in clinical practice.</p>","PeriodicalId":7578,"journal":{"name":"American Journal of Hypertension","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143603399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Orthostatic Hypertension in Childhood: Filling the Gap of Information on the Phenotype.","authors":"Stella Stabouli, Guido Grassi","doi":"10.1093/ajh/hpaf032","DOIUrl":"https://doi.org/10.1093/ajh/hpaf032","url":null,"abstract":"","PeriodicalId":7578,"journal":{"name":"American Journal of Hypertension","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143603410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Day-to-day blood pressure variability and cognitive function in the elderly with acute heart failure.","authors":"Michiaki Nagai, Keigo Dote, Masaya Kato, Noboru Oda, Faddi G Saleh Velez, Tarun Dasari","doi":"10.1093/ajh/hpaf030","DOIUrl":"https://doi.org/10.1093/ajh/hpaf030","url":null,"abstract":"<p><strong>Background: </strong>Heart failure (HF) and cognitive impairment often occur together in older adults. Although earlier studies have reported an association between blood pressure (BP) variability (BPV) and cognitive impairment, the underlying pathophysiology remains unclear in HF. In this study, the hypothesis that higher BPV is associated with cognitive impairment was evaluated in the elderly patients with acute decompensated HF (ADHF).</p><p><strong>Methods: </strong>Day-to-day in-hospital BPV and cognitive function using a mini-mental state examination (MMSE) were assessed in 245 elderly patients (82.9 ± 6.0 years, 49.4% male) with ADHF. Based on the data of 7 days, day-to-day BPV (expressed as the standard deviation [SD], coefficient of variation [CV], maximum BP, minimum BP, and δ [maximum-minimum] BP) were measured.</p><p><strong>Results: </strong>According to MMSE score quartiles, significant differences were observed in SD (8.2 vs 6.2 vs 6.7 mmHg, p<0.001), CV (13.3 vs 9.94 vs 10.9 %, p<0.001) and δ (22.8 vs 17.5 vs 18.6 mmHg, p<0.001) in diastolic blood pressure (DBP) between three groups. In the logistic regression analysis adjusted for the confounders, SD (OR: 1.23, p<0.01), CV (OR: 1.12, p<0.01), maximum (OR: 1.13, p<0.001) and δ (OR: 1.07, p<0.01) in DBP were significantly associated with the lowest quartile of MMSE score. In the stratified analysis by HF phenotypes, significant associations of day-to-day DBP variability were found with the lowest quartile of MMSE score specifically in the HF with preserved ejection fraction group (HFpEF).</p><p><strong>Conclusions: </strong>Cognitive impairment in association with day-to-day BPV is increasingly prevalent in elderly patients presenting with ADHF, specifically in HFpEF.</p>","PeriodicalId":7578,"journal":{"name":"American Journal of Hypertension","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143603405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Switching from ARBs to sacubitril/valsartan safely improves 24-hour ambulatory blood pressure in patients with advanced chronic kidney disease.","authors":"Sho Kinguchi, Kohei Ishiga, Hiromichi Wakui, Kengo Azushima, Tomohiko Kanaoka, Yusuke Kobayashi, Tatsuya Haze, Nobuhito Hirawa, Kouichi Tamura","doi":"10.1093/ajh/hpaf028","DOIUrl":"https://doi.org/10.1093/ajh/hpaf028","url":null,"abstract":"<p><strong>Background: </strong>We investigated the effects of sacubitril/valsartan, a first-in-class angiotensin receptor neprilysin inhibitor (ARNI), on 24-hour blood pressure (BP) and safety for 12 weeks in Japanese patients with non-dialysis advanced chronic kidney disease (CKD).</p><p><strong>Methods: </strong>We conducted a prospective, single-arm exploratory study. Patients with non-dialysis CKD stage G4-5 (estimated glomerular filtration (eGFR) <30 mL/min/1.73 m2) who did not achieve their BP goals with angiotensin receptor blocker (ARB) administration, were enrolled and switched to sacubitril/valsartan. Primary and key secondary endpoints were changes from baseline in the 24-hour systolic BP (SBP) measured via ambulatory BP monitoring (ABPM) over 12 weeks and the safety, especially incidence of serum creatinine (Cr) increase (≥30% increase from baseline) and hyperkalemia.</p><p><strong>Results: </strong>Thirty patients were enrolled, and 29 patients were switched to sacubitril/valsartan. Efficacy analysis was conducted on 26 patients. Baseline mean eGFR and office BP were 21.1±5.0 mL/min/1.73m2 and 149.4±23.7/80.7±11.9 mmHg, respectively. Baseline 24-hour, daytime, and nighttime BP were 139.6±17.7/77.0±7.8 mmHg, 143.5±18.5/79.6±8.7 mmHg, and 131.0±20.4/71.1±8.8 mmHg, respectively. After 12 weeks, changes in 24-hour, daytime, and nighttime SBP from baseline were -7.1±12.4 mmHg (P <0.01), -7.7±12.9 mmHg (P <0.01), and -5.8±15.8 mmHg (P = 0.07), respectively. No incidences of potassium values >6.0 mmol/L or serum Cr ≥30% increase from baseline were reported after sacubitril/valsartan initiation.</p><p><strong>Conclusions: </strong>Switching from ARB to sacubitril/valsartan can safely enhance 24-hour antihypertensive treatment in patients with non-dialysis CKD G4-5 who do not achieve BP goals with ARBs.CLINICAL TRIALS REGISTRATION: Trial Number jRCT1031220149.</p>","PeriodicalId":7578,"journal":{"name":"American Journal of Hypertension","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143596116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plasmacytoid dendritic cell content is associated with plasma aldosterone concentration in patients with primary aldosteronism.","authors":"Anna M Imiela, Tomasz P MikoŁAjczyk, Sylwia KoŁOdziejczyk-Kruk, Jacek KĄDziela, Mateusz Spiewak, Magdalena Januszewicz, Marek Kabat, Ignacy SterliŃSki, Marcin Wąs, Aleksandra WrÓBel, Dominik Skiba, Joanna Natorska, Tomasz J Guzik, Andrzej Januszewicz","doi":"10.1093/ajh/hpaf019","DOIUrl":"10.1093/ajh/hpaf019","url":null,"abstract":"<p><strong>Background: </strong>Inflammation plays a pivotal role in blood pressure regulation. Current data reflect the important role of T cells in primary hypertension. The role of dendritic cells (DC) in secondary hypertension- primary aldosteronism (PA) remains unknown. The aim of this study was to quantify peripheral blood T lymphocytes, plasmacytoid dendritic cells (pDCs) and inflammatory markers in individuals with PA comparing to essential hypertension (HTN).</p><p><strong>Methods: </strong>39 patients with PA and 15 patients with HTN were enrolled. Clinical data, serum aldosterone concentration, ambulatory blood pressure monitoring (ABPM), echocardiography, and phenotype of peripheral blood cells with the usage of flow cytometry were assessed.</p><p><strong>Results: </strong>No differences were found in terms of age, sex and BMI between the groups. In both groups, similar levels of systolic and diastolic blood pressure on ABPM were noted. Both PA and HTN were associated with cardiac hypertrophy (LVMI). In comparison with HTN, PA patients had a notably higher percentage of pDC characterized by co-expression of CD123 and CD303. A positive correlation between aldosterone concentration and the percentage of CD123+CD303+ pDC in the PA was observed. The PA group exhibited lower concentrations of RANTES, TNF-α, CD40L, and VEGF compared to the HTN group.</p><p><strong>Conclusions: </strong>Higher aldosterone concentration was connected with the increased numbers of plasmacytoid pDC.</p>","PeriodicalId":7578,"journal":{"name":"American Journal of Hypertension","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143582162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}